Current liabilities increased 19.2%
Current liabilities changed +19.2% from the comparable as-filed period.
Ranked by interpretable importance, issuer history, magnitude, and accounting profile. No directional recommendation.
Current liabilities changed +19.2% from the comparable as-filed period.
Current ratio changed +89.5% from the comparable as-filed period.
Working capital / assets changed +1112 basis points from the comparable as-filed period.
Operating cash-flow margin changed +6489 basis points from the comparable as-filed period.
Free-cash-flow margin changed -2547 basis points from the comparable as-filed period.
R&D / revenue changed -428 basis points from the comparable as-filed period.
Operating cash flow / net income changed +74.5% from the comparable as-filed period.
SBC / revenue changed -170 basis points from the comparable as-filed period.
Working capital changed +153.3% from the comparable as-filed period. Relative percentage is de-emphasized because the comparison has a sign change.
Research & development changed -3.6% from the comparable as-filed period. This reverses 2 consecutive comparable moves in the opposite direction.
Receivables / revenue changed -35 basis points from the comparable as-filed period. This reverses 2 consecutive comparable moves in the opposite direction.
Stock-based compensation changed +0.3% from the comparable as-filed period.
Net income changed +26.7% from the comparable as-filed period.
Free-cash-flow proxy changed -16274.6% from the comparable as-filed period. Relative percentage is de-emphasized because the comparison has a sign change.
Working capital / assets changed +546 basis points from the comparable as-filed period.
Current ratio changed +32.5% from the comparable as-filed period.
Operating margin changed +94 basis points from the comparable as-filed period.
Working capital changed +2767.5% from the comparable as-filed period. Relative percentage is de-emphasized because the comparison has a low base.
Free-cash-flow margin changed -6731 basis points from the comparable as-filed period.
Receivables / revenue changed +538 basis points from the comparable as-filed period.
R&D / revenue changed -202 basis points from the comparable as-filed period.
Research & development changed +7.3% from the comparable as-filed period.
SBC / revenue changed -75 basis points from the comparable as-filed period.
Stock-based compensation changed +10.9% from the comparable as-filed period.
Operating cash flow / net income changed -4.9% from the comparable as-filed period.
Operating cash-flow margin changed -39 basis points from the comparable as-filed period.
Method Importance combines metric-family relevance, magnitude, issuer-history unusualness, persistence, and financial-statement significance. It is analytical prioritization, not a legal materiality conclusion or investment signal.